Journal of Pharmaceutical Sciences 2013-03-01

Minimally invasive transdermal delivery of iron-dextran.

Abhishek Juluri, Naresh Modepalli, Seongbong Jo, Michael A Repka, H Nanjappa Shivakumar, S Narasimha Murthy

Index: J. Pharm. Sci. 102(3) , 987-93, (2013)

Full Text: HTML

Abstract

Iron deficiency is one of the most prevalent and serious health issues among people all over the world. Iron-dextran (ID) colloidal solution is one among the very few US Food and Drug Administration (FDA)-approved iron sources for parenteral administration of iron. Parenteral route does not allow frequent administration because of its invasiveness and other associated complications. The main aim of this project was to investigate the plausibility of transdermal delivery of ID facilitated by microneedles, as an alternative to parenteral iron therapy. In vitro permeation studies were carried out using freshly excised hairless rat abdominal skin in a Franz diffusion apparatus. Iron repletion studies were carried out in hairless anemic rat model. The anemic rats were divided into intact skin (control), microneedle pretreated, and intraperitoneal (i.p.) groups depending on the mode of delivery of iron. The hematological parameters were measured intermittently during treatment. There was no improvement in the hematological parameters in case of control group, whereas, in case of microneedle pretreated and i.p. group, there was significant improvement within 2-3 weeks. The results suggest that microneedle-mediated delivery of ID could be developed as a potential treatment method for iron-deficiency anemia.Copyright © 2012 Wiley Periodicals, Inc.

Related Compounds

Structure Name/CAS No. Articles
Iron dextran Structure Iron dextran
CAS:9004-66-4